Novo Nordisk's Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.

DaVita Inc. stock has been heavily sold in '23, trading below its 50-day moving average for the past 8 weeks. The company lacks economic value, and its reinvestment runway looks limited, producing ...

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the lat...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and RDNT are well-poi...

U.S. Steel (NYSE: X ) announced on Aug. 13 that it was undertaking a strategic review to maximize shareholder value. Once the country's largest steelmaker, it was removed as a constituent of S&P 50...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the lat...

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.